James Oliviero | Source | CEO and President at Checkpoint Therapeutics
Mr. Oliviero is the President and CEO of Checkpoint Therapeutics, a member of Checkpoint’s Board of Directors and has more than twenty years of operational experience in the biotechnology industry. Prior to Checkpoint, Mr. Oliviero served in a variety of leadership roles, most recently as Chief Financial Officer at Keryx Biopharmaceuticals, where he played a key role in growing the company to a market capitalization over $1 billion and completed over $500 million in various public financings.
-
My love is clinical development; bringing new, potentially life-saving therapies to the patients who need them. I joined Checkpoint in 2015 after successfully developing and launching a new drug at my former company. I was attracted to Checkpoint for its interesting and cutting-edge pipeline of immunotherapy products. Cancer affects too many of us in so many ways, and so I’m driven to bring our oncology drugs to market and have a positive impact on our world.
7 September 2021
-
7 September 2021articleGet to Know James Oliviero, CEO and President of Checkpoint Therapeutics | BioSpaceBioSpace recently spoke with James Oliviero, CEO and president at Checkpoint Therapeutics, an immuno-oncology, late-stage development company.
-
Checkpoint Therapeutics
CEO and President